Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 2, Pages 158-168
Publisher
Elsevier BV
Online
2021-10-29
DOI
10.1016/j.annonc.2021.10.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Commentary: SARS-CoV-2 vaccines and cancer patients
- (2021) C. Corti et al. ANNALS OF ONCOLOGY
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
- (2021) Anthony T. Tan et al. Cell Reports
- Vaccination anti COVID-19 pour les personnes souffrant de cancer : un impératif médical et éthique
- (2021) Jean-Philippe Spano et al. BULLETIN DU CANCER
- Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action
- (2021) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- COVID-19 vaccination: the VOICE for patients with cancer
- (2021) Astrid A. M. van der Veldt et al. NATURE MEDICINE
- Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
- (2021) Andrew R. Branagan et al. Blood Advances
- Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey
- (2021) J. Barrière et al. ANNALS OF ONCOLOGY
- Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
- (2021) J. Barrière et al. ANNALS OF ONCOLOGY
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
- (2021) Yair Herishanu et al. BLOOD
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
- (2021) Fulvia Pimpinelli et al. Journal of Hematology & Oncology
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
- (2021) Barliz Waissengrin et al. LANCET ONCOLOGY
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
- (2021) Leticia Monin et al. LANCET ONCOLOGY
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
- (2021) Aakash Desai et al. Nature Reviews Clinical Oncology
- BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies
- (2021) Katrin Herzog Tzarfati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impaired response to first SARS‐CoV ‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
- (2021) Paola Guglielmelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
- (2021) William A. Werbel et al. ANNALS OF INTERNAL MEDICINE
- 1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study
- (2021) S.T.C. Shepherd et al. ANNALS OF ONCOLOGY
- Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients
- (2021) P. Heudel et al. ANNALS OF ONCOLOGY
- Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies
- (2021) Paola Ghione et al. BLOOD
- Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients
- (2021) Magdalena Benda et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms
- (2021) Onima Chowdhury et al. BRITISH JOURNAL OF HAEMATOLOGY
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- (2021) Astha Thakkar et al. CANCER CELL
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
- (2021) Oliver Van Oekelen et al. CANCER CELL
- Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
- (2021) Sidse Ehmsen et al. CANCER CELL
- Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
- (2021) Elizabeth A. Griffiths et al. CANCER CELL
- Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
- (2021) Mario Mairhofer et al. CANCER CELL
- Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
- (2021) Laura Mansi et al. EUROPEAN JOURNAL OF CANCER
- Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer
- (2021) Jérôme Barrière et al. EUROPEAN JOURNAL OF CANCER
- Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
- (2021) Cengiz Karacin et al. Future Oncology
- Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia
- (2021) Ohad Benjamini et al. HAEMATOLOGICA
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
- (2021) Ilies Benotmane et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
- (2021) Evangelos Terpos et al. Journal of Hematology & Oncology
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
- (2021) Xinxue Liu et al. LANCET
- Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
- (2021) Samuel D. Stampfer et al. LEUKEMIA
- A French cohort for assessing COVID-19 vaccine responses in specific populations
- (2021) Paul Loubet et al. NATURE MEDICINE
- A correlate of protection for SARS-CoV-2 vaccines is urgently needed
- (2021) Florian Krammer NATURE MEDICINE
- High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
- (2021) Nathalie Longlune et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
- (2021) Nassim Kamar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
- (2021) Victoria G. Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
- (2021) Yinon M. Bar-On et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
- (2021) H. Parry et al. Blood Cancer Journal
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
- (2021) Kazimieras Maneikis et al. Lancet Haematology
- Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
- (2021) Sean H Lim et al. Lancet Haematology
- Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
- (2021) Noa Eliakim-Raz et al. JAMA Oncology
- Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer
- (2021) Tal Goshen-Lago et al. JAMA Oncology
- Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
- (2021) Nader Yatim et al. Science Advances
- Cancer Patients’ Willingness to Take COVID-19 Vaccination: A Nationwide Multicenter Survey in Korea
- (2021) June Young Chun et al. Cancers
- Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
- (2021) Susanne Ghandili et al. Cancers
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
- (2021) C. Perry et al. Blood Advances
- High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
- (2021) R. Palich et al. ANNALS OF ONCOLOGY
- SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
- (2021) Flora Zagouri et al. BREAST
- Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution
- (2021) Vincenzo Di Noia et al. CLINICAL CANCER RESEARCH
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
- (2020) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
- (2020) Mark J. Mulligan et al. NATURE
- Factors associated with COVID-19-related death using OpenSAFELY
- (2020) Elizabeth J. Williamson et al. NATURE
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- Risk factors for COVID-19 severity and mortality among solid cancer patients and its impact on anticancer treatment: a nationwide cohort study (GCO-002 CACOVID-19)
- (2020) Astrid Lièvre et al. EUROPEAN JOURNAL OF CANCER
- Dutch Oncology COVID-19 Consortium (DOCC): outcome of COVID-19 in patients with cancer in a nationwide cohort study
- (2020) K. de Joode et al. EUROPEAN JOURNAL OF CANCER
- A Systematic Review and Meta-Analysis: The Effect of Active Cancer Treatment on Severity of COVID-19
- (2020) Emre Yekedüz et al. EUROPEAN JOURNAL OF CANCER
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccination and Immune Checkpoint Inhibitors
- (2020) Anne-Laure Desage et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Previsit Screening for Parental Vaccine Hesitancy: A Cluster Randomized Trial
- (2019) Douglas J. Opel et al. PEDIATRICS
- Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults
- (2012) D.V. Potsch et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started